PE-22-28 (10mg) — Research Compound
PE-22-28 is a synthetic peptide derived from spadin, studied for its role as a selective blocker of the TREK-1 potassium channel. TREK-1 is primarily expressed in the brain, particularly in areas associated with mood and cognitive function, such as the hippocampus. Researchers investigate PE-22-28 for its potential to act as a rapid-onset antidepressant by modulating neuronal excitability and stimulating neurogenesis without the lag time associated with traditional serotonergic therapies.
Findings from early-stage clinical trials have reported:
• Rapid improvements in mood-related behavioral markers observed within four days in experimental models.
• Significant increases in the levels of Brain-Derived Neurotrophic Factor (BDNF) reported in hippocampal research.
• Enhanced rates of neurogenesis (new neuron growth) noted across multiple study cohorts.
• No observed impact on cardiovascular markers or traditional potassium channel side effects in research studies.
Researchers study PE-22-28 to investigate the role of TREK-1 signaling in the regulation of mental health and neuroplasticity. Its ability to trigger neurogenic pathways rapidly makes it a specialized tool for understanding the biological response to acute stress. This compound is a primary focus for research into the next generation of fast-acting neurotrophic agents and the mechanisms of neuronal resilience.
Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.
Used solely for in vitro experiments and cannot be:
- Used in clinical trials involving humans
- Administered to humans as part of an experiment or investigation
- Supplied to another party for human investigational use
References
Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activity
This study identified PE-22-28 as a shortened spadin analogue with strong TREK-1 channel inhibition and improved research stability compared with earlier spadin peptides.
Source Link: Available here
PE-22-28 and TREK-1 channel inhibition research
This PubMed-indexed reference supports PE-22-28’s role as a spadin-derived peptide studied for TREK-1 inhibition and neurobiological pathway research.
Source Link: Available here
Role of TREK-1 in health and disease with focus on the central nervous system
This review discusses TREK-1 biology and includes PE-22-28 as a shorter peptide sequence with high TREK-1 inhibition potency, supporting its neurological research context.
Source Link: Available here
Certificate of Analysis (COA): Available here
| IDENTIFICATION | |
| Product Name | PE-22-28 10 mg |
| Catalogue Number | RP-PE2228-01 |
| CAS Number | 1801959-12-5 |
| Molecular Weight (g/mol) | 840.9 g/mol |
| Molecular Formula | C36H60N10O11 |
| Peptide Sequence | Endorphin fragment (aa 22–28) |
| PHYSICAL AND CHEMICAL PROPERTIES | |
| Active Ingredient | PE-22-28 |
| Appearance | White to off-white lyophilised powder |
| Melting Point | Not applicable (decomposes before melting) |
| ANALYTICAL AND QUALITY CONTROL | |
| Mass Spectrum | Conforms to specification |
| Structural Confirmation | Consistent with theoretical structure / sequence |
| RESEARCH USE AND SAFETY | |
| Caution | Handle using appropriate PPE and in compliance with relevant laboratory safety standards. |
| Intended Use | For laboratory research use only. Not for human or veterinary use. |
| Hazard Classification | Not classified as hazardous under GHS for research quantities |
| STORAGE, HANDLING AND STABILITY | |
| Storage Temperature, Opened | -20 °C, minimise freeze–thaw cycles |
| Storage Temperature, Unopened | -20 °C recommended for long-term storage |
| Shelf Life | 2 years unopened under recommended conditions |
| Reconstitution Stability | Stable for up to 28 days at 2–8 °C in aqueous solution under sterile conditions |
Certificate of Analysis – PE-22-28 (99% Purity Verified)
| COMPOUND IDENTIFICATION | |
| Product Name | PE-22-28 |
| Batch / Reference ID | PE300901 |
| Sample Form | White powder in glass vial |
| ANALYTICAL RESULTS | |
| Chemical Purity | 99% (Verified) |
| Measured Content | 10.11 mg (± 0.05 mg) |
| Test Method | HPLC (High-Performance Liquid Chromatography) |
| LABORATORY TESTING INFORMATION | |
| Analysis Period | 06 Feb 2026 – 10 Feb 2026 |
| Laboratory Order # | 100012234 |
| QUALITY ASSURANCE | |
| Quality Testing Standards | All River Peptides products undergo batch-level laboratory analysis to verify compound identity and confirm purity levels. Learn more on our Quality Testing & Purity Verification page. |
Related Products
